Clinical Trials · NCT07340827
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Enrollment
- 266
- Start date
- Feb 2026
- Locations
- 21 sites, Japan
- Primary endpoint
- Total number of oocytes retrieved